Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I
AssigneesH. Lee Moffitt Cancer Center and Research Institute, Inc., Yale University
InventorsSaid M. Sebti, Andrew Hamilton
Life of this patent
Estimating the term…
Loading patent…
AssigneesH. Lee Moffitt Cancer Center and Research Institute, Inc., Yale University
InventorsSaid M. Sebti, Andrew Hamilton
Estimating the term…
Many GTPases such as Ras, Ral and Rho require post-translational farnestylation or geranylgeranylation for mediating malignant transformation. Dual farnesyltransferase (FT) (FTI) and geranylgeranyltransferase-I (GGT-1) inhibitors (GGTI) were developed as anticancer agents from based on an ethylenediamine scaffold. On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating extensive structure-activity relationship studies. The most potent inhibitor is compound exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Several of the inhibitors proved highly selective for hFTase over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of an inhibitor cocrystallized with farnesyl pyrophosphate in the active site of rat FTase illustrates that the para-benzonitrile moiety is stabilized by a π-π stacking interaction with the Y361β residue, suggesting an importance of this component of the inhibitors.
A composition, wherein the composition further comprises a compound of the general formula:
A method of treating cancer comprising administering a compound having the general formula:
Dependencies are inferred from the claim text.